Abstract Number: 1284 • 2012 ACR/ARHP Annual Meeting
Evaluation of Influenza and Pneumococcal Vaccine Responses in Patients with Rheumatoid Arthritis Receiving Tofacitinib
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. Clinical guidelines recommend the use…Abstract Number: 1285 • 2012 ACR/ARHP Annual Meeting
Short-Term Efficacy of Etanercept Plus Methotrexate Vs.Various Disease-Modifying Anti-Rheumatic Combinations with Methotrexate in Established Rheumatoid Arthritis
Background/Purpose: The objective of this study was to assess the short-term benefit of etanercept (ETN) + methotrexate (MTX) vs. various disease-modifying anti-rheumatic drugs (DMARDs; hydroxychloroquine…Abstract Number: 1286 • 2012 ACR/ARHP Annual Meeting
Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab
Background/Purpose: To determine if RA patients (pts) who had an inadequate response to etanercept(ETN) or adalimumab(ADA) and developed antibodies (Abs) to ETN or ADA responded…Abstract Number: 1287 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Comparison of Active Therapies in Methotrexate Suboptimal Responders: Validation of the Strategy of Conventional Disease Modifying Anti-Rheumatic Drugs Before Biologicals
Background/Purpose: Double-blind placebo controlled randomized trials have demonstrated the efficacy of 15 different therapies in RA patients with active disease despite methotrexate (MTX). No blinded…Abstract Number: 1288 • 2012 ACR/ARHP Annual Meeting
A Significant Number of Patients with Chronic Arthritis Received a Reduced Dosage of Biological Drugs: an Observational Study in Clinical Practice
Background/Purpose: Biological agents are used to treat chronic arthritis according to the standard dosages from phase III clinical trials. However, in some patients, a good…Abstract Number: 1289 • 2012 ACR/ARHP Annual Meeting
Abatacept Biologic-Free Remission Study in Established Rheumatoid Arthritis Patients. Orion Study
Background/Purpose: Abatacept (ABA) has comparable efficacy to TNF inhibitors in achieving clinical remission in rheumatoid arthritis (RA) patients. However, although clinical evidence suggests that biologic-free…Abstract Number: 1290 • 2012 ACR/ARHP Annual Meeting
Effects of Tofacitinib On Lipid Profiles and Cholesterol and Lipoprotein Kinetics in Patients with Rheumatoid Arthritis
Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. In RA patients (pts), suppression…Abstract Number: 1291 • 2012 ACR/ARHP Annual Meeting
A Phase Ib Clinical Trial with F8-IL10, an Anti-Inflammatory Immunocytokine for the Treatment of Rheumatoid Arthritis (RA), Used in Combination with Methotrexate (MTX)
Background/Purpose: Interleukin 10 (IL10) is an anti-inflammatory cytokine potentially efficacious for RA. F8-IL10 is a fusion protein in which the cytokine is fused with the…Abstract Number: 1292 • 2012 ACR/ARHP Annual Meeting
Fatigue Is an Independent Variable Predicting Physical Function and Disease Activity Score-28 Remission for Patients with Rheumatoid Arthritis Treated with Intravenously Administered Golimumab: Results From Phase 3, Placebo Controlled Clinical Trial
Background/Purpose: To evaluate the association of fatigue with physical function and disease activity in patients with rheumatoid arthritis (RA), and the impact of treatment with…Abstract Number: 1293 • 2012 ACR/ARHP Annual Meeting
Importance of Steady-State Trough Concentrations After Intravenous Golimumab with Concomitant Methotrexate in Subjects with Active Rheumatoid Arthritis
Background/Purpose: To determine an optimized dosing regimen for IV golimumab in subjects with active RA using population pharmacokinetic (PK) modeling and simulation. Methods: Two Phase…Abstract Number: 1294 • 2012 ACR/ARHP Annual Meeting
A Phase Ib Multiple Ascending Dose Study Evaluating Safety, Pharmacokinetics, and Early Clinical Response of Brodalumab (AMG 827), a Human Anti-Interleukin 17 Receptor (IL-17R) Antibody, in Rheumatoid Arthritis
Background/Purpose: The cytokine IL-17A is an innate inflammatory cytokine implicated in the pathogenesis of several human autoimmune diseases including rheumatoid arthritis (RA). Brodalumab is…Abstract Number: 1295 • 2012 ACR/ARHP Annual Meeting
Effectiveness and Tolerability of Subcutaneous Tocilizumab in Rheumatoid Arthritis Patients Switched From Intravenous Tocilizumab: Results From the Extension Period of the Musashi Study
Background/Purpose: In the MUSASHI study (i.e., Double-blind, parallel-group, Phase III non-inferiority study comparing subcutaneous tocilizumab [SC-TCZ] monotherapy versus intravenous tocilizumab [IV-TCZ] monotherapy), the effectiveness and…Abstract Number: 1256 • 2012 ACR/ARHP Annual Meeting
High Inflammation May Condition the Antiatherogenic Function of Small, Dense HDL in Patients with Active Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased mortality, mainly due to cardiovascular disease. High grade inflammation might drive to premature atherosclerosis. High-density lipoprotein (HDL)…Abstract Number: 1257 • 2012 ACR/ARHP Annual Meeting
Subclinical Atherosclerosis in Hispanic Patients with Rheumatoid Arthritis. Correlation with the Presence of Anti-Oxidized LDL Antibodies and Serum Levels of CD40L
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease, associated with an excess of cardiovascular morbidity and mortality due to accelerated atherosclerosis. The appearance of…Abstract Number: 1258 • 2012 ACR/ARHP Annual Meeting
Association Between Low Vitamin D Levels and Indicators of Osteoporosis and Atherosclerosis
Background/Purpose: Osteoporosis and cardiovascular disease are complications of chronic rheumatoid arthritis (RA). It is not known if these processes share pathogenetic mechanisms. Low levels of…
ACR Meeting Abstracts